CFTR modulator theratyping: Current status, gaps and future directions
John P. Clancy(Cystic Fibrosis Foundation), Katherine L. Tuggle(University of Alabama at Birmingham), Scott H. Donaldson(University of North Carolina at Chapel Hill), William R. Skach(Cystic Fibrosis Foundation), Donald R. VanDevanter(Case Western Reserve University), Martina Gentzsch(University of North Carolina at Chapel Hill), Jeffrey M. Beekman(Utrecht University), Anthony G. Durmowicz(Cystic Fibrosis Foundation), Jerry A. Nick(University of Colorado Denver), Drucy Borowitz(Cystic Fibrosis Foundation), Robert J. Bridges(Rosalind Franklin University of Medicine and Science), Philip Thomas(Southwestern Medical Center), Elizabeth Joseloff(Cystic Fibrosis Foundation), Eric J. Sorscher(Emory University), Steven M. Rowe(University of Alabama at Birmingham), J. Wallenburg(Cystic Fibrosis Canada), Calvin U. Cotton(Case Western Reserve University), George M. Solomon(University of Alabama at Birmingham), K. De Boeck(Universitair Ziekenhuis Leuven), Garry R. Cutting(Johns Hopkins University), Christopher M. Penland(Cystic Fibrosis Foundation), Anjaparavanda P. Naren(Cincinnati Children's Hospital Medical Center), Hermann Bihler(Cystic Fibrosis Foundation), Margarida D. Amaral(Lusíada University of Lisbon), Beate Illek(UCSF Benioff Children's Hospital), Michael Boyle(Royal College of Surgeons in Ireland), Martin Mense(Cystic Fibrosis Foundation), John E. Mahoney(Cystic Fibrosis Foundation)
Cited by 288
Related Papers
Update on Key Emerging Challenges in Cystic Fibrosis
|Medical Principles and Practice|2014|3.7k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k